10.6084/M9.FIGSHARE.6007691
Katherine A. Lyseng-Williamson
Olmesartan medoxomil/amlodipine/hydrochlorothiazide 20 mg/5 mg/12.5 mg fixed-dose combination in hypertension: a profile of its use
<p><i>Conflicts of interest:</i> K.A. Lyseng-Williamson is a
salaried employee of Adis/Springer, is responsible for the article content and
declares no relevant conflicts of interest.</p>
<p><i>Funding</i>: The preparation of this review was
not supported by any external funding. </p>
<p>Additional information about this
Adis Drug Review may be found <a href="http://www.springer.com/gp/adis/products-services/adis-journals-newsletters/adis-drug-reviews"><b>here</b></a>.</p>
<p>Abstract</p>
<p>The triple-component
fixed-dose combination of olmesartan medoxomil (OLM)/amlodipine
(AML)/hydrochlorothiazide (HCT) is a rational choice for patients who require
treatment with three or more antihypertensives. The three drugs in the FDC have
complementary mechanisms of action, with OLM, AML and HCT being an angiotensin
II receptor blocker, calcium channel blocker and diuretic, respectively.
Once-daily OLM/AML/HCT 20 mg/5 mg/12.5 mg reduced systolic and
diastolic blood pressure, thereby enabling patients to achieve blood pressure
goals, and was generally well tolerated in clinical trials. Moreover, the use
of a fixed-dose combination comprising three antihypertensive components
reduces pill burden, which may improve patient adherence to treatment and, ultimately,
clinical outcomes. </p><p>Access to the full article can be found <a href="https://link.springer.com/article/10.1007/s40267-017-0465-z"><b>here</b></a>.<br></p><p><br></p>
<p>©
Springer International Publishing AG, part of Springer Nature 2017</p>
Medicine
Adis Journals
2018
2018-03-20
2018-03-28
Online resource
0 Bytes
CC BY-NC 4.0